Company Management

SELLAS Life Sciences Group, Inc.

Biotechnology Research 7 Times Square 20 employees

Employees: 20
Contacts: 2
Emails: 2
Phones: 1

sellaslifesciences.com LinkedIn

SELLAS Life Sciences Group, Inc. Overview

Headquarters: 7 Times Square
Phone Number: Available in AeroLeads
Website: sellaslifesciences.com
Industry: Biotechnology Research
Employees: 20
Founded: 2012
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Biopharma oncology late stage clinical trials immunotherapies hematologic oncology

About SELLAS Life Sciences Group, Inc.

We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. Our second product candidate, GFH009, is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor licensed from GenFleet Therapeutics, which we hold the exclusive rights to for further development and commercialization of the asset across all therapeutic and diagnostic uses outside of greater China. GPS and GFH009 have potential as monotherapies, or in combination with other therapies, to address a broad spectrum of hematologic malignancies and solid tumor indications.

SELLAS Life Sciences Group, Inc. Contact Details

People in AeroLeads: 4
With contact data: 2
Email contacts: 2; 50.0% coverage
Phone contacts: 1; 25.0% coverage

SELLAS Life Sciences Group, Inc. Org Chart

Sample employees and titles

Name	Title	Location	Contact
Lisa Pantano	Director Quality Control and Assurance		View
Andrew Elnatan		Greater Boston, United States	Email
Nancy D. Ecklund	Senior Director, Human Resources	New York, United States	Email Phone
Jane Wasman	Experienced Corporate Board Chair/life		View